Mekinist (trametinib) — Medica

Initial criteria

• Patient meets ONE of the following (i or ii): i) Patient has BRAF V600 mutation-positive disease; OR ii) Patient has BRAF fusion-positive disease
• Patient meets ONE of the following (i or ii): i) The medication will be taken in combination with Tafinlar (dabrafenib); OR ii) Patient has circumscribed glioma

Approval duration

1 year